Inflammatory bowel disease (IBD) is an umbrella term for immune response-mediated chronic remission and relapse bowel diseases that result in the chronic inflammation of intestines, causing pain and swelling. Although there is no effective cure to date, there has been extensive research on IBD and gut microbiota that has led to insights that may result in effective therapeutic interventions. This new volume, Inflammatory Bowel Disease and Gut Microbiota: Current Strategies and Future Prospects in Nanomedicine, delves into the intricacies of this research, highlighting the novel methodologies and innovative approaches in the treatment of IBD in conjunction with the role of gut microbiota.

The book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota in the advancement and progression of IBD. It investigates the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes, as well as the prominent therapeutic consequences of restoring microbial homeostasis in the context of treatment techniques. The book explores nanotechnology and nanomedicine as a promising field in this regard. It provides a detailed overview of nanotechnological advancement for specific and efficient treatments for IBD. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicaments to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD. The volume also anticipates future expansions, engaging in speculation on probable progresses and the obstacles that may be confronted.

Contents

۱. Introduction to Gut Microbiota and Inflammatory Bowel Disease: A Systematic Review
۲. Pathogenesis of Gut Microbiota in Inflammatory Bowel Disease (IBD)
۳. Impact of Nutraceuticals on Gut Microbiota for the Management of IBD
۴. Targeting Gut Microbiota with a Novel Drug Delivery System to Treat Inflammatory Bowel Disease (IBD)
۵. Management of Gut Microbiota-Derived Bacterial Metabolites-Induced IBD
۶. Correlation Between Host Genetics and Gut Microbiota in (IBD)
۷. Oral siRNA-Based Nanomedicine for the Treatment of IBD
۸. Site-Specific Targeted Novel Drug Delivery System for the Management of IBD
۹. Surface-Modified Lipid Nanoparticle-Mediated Site-Specific Drug Delivery for IBD
۱۰. Interplay Between Autophagy, Gut Microbiota, and IBD
۱۱. Role of Reactive Oxygen Species (ROSs), Superoxide Dismutases (SODs), and Inflammation in Association with Gut Microbiota and IBD
۱۲. Composition of Gut Microbiota Dysbiosis and Functional Food to Treat Inflammatory Bowel Disease (IBD)
۱۳. Age-Related Gut Dysbiosis and Its Impact on IBD
۱۴. Impact of Diseased Condition on Gut Microbiota in IBD
۱۵. Role of Probiotics and Prebiotics in IBD
۱۶. Application of Natural Products in Targeting Gut Microbiota for IBD Management
۱۷. Future Prospects and Patents of Nanomedicines in Treating Inflammatory Bowel Disease

Contents

Part I: Epistemological Considerations About the Study of Normal and Abnormal Human Behaviours
Part II: From Basic Neurosciences to Human Brain
Part III: Neurosciences, Learning, Teaching and the Role of Social Environment
Part IV: Explaining Human Pathological Behaviors. From Brain Disorders to Psychopathology